Advertisement

Anti-Interleukin-6 Antibodies for Autoimmune Retinopathy with Macular Edema

Published:August 25, 2021DOI:https://doi.org/10.1016/j.oret.2021.08.008

      Abstract

      In this cohort of patients with non-paraneoplastic autoimmune retinopathy and cystoid macular edema (CME), treatment with anti-interleukin-6 antibodies was associated with reduced CME, partial restoration of the ellipsoid zone on optical coherence tomography, and a trend towards improved visual acuity.

      Key Words

      To read this article in full you will need to make a payment
      Subscribe to Ophthalmology Retina
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References:

        • Grewal D.S.
        • Fishman G.A.
        • Jampol L.M.
        Autoimmune retinopathy and antiretinal antibodies: a review.
        Retina Phila Pa. 2014; 34: 827-845https://doi.org/10.1097/IAE.0000000000000119
        • Ferreyra H.A.
        • Jayasundera T.
        • Khan N.W.
        • He S.
        • Lu Y.
        • Heckenlively J.R.
        Management of autoimmune retinopathies with immunosuppression.
        Arch Ophthalmol Chic Ill 1960. 2009; 127: 390-397https://doi.org/10.1001/archophthalmol.2009.24
        • Davoudi S.
        • Ebrahimiadib N.
        • Yasa C.
        • et al.
        Outcomes in Autoimmune Retinopathy Patients Treated With Rituximab.
        Am J Ophthalmol. 2017; 180: 124-132https://doi.org/10.1016/j.ajo.2017.04.019
        • Vegas-Revenga N.
        • Calvo-Río V.
        • Mesquida M.
        • et al.
        Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
        Am J Ophthalmol. 2019; 200: 85-94https://doi.org/10.1016/j.ajo.2018.12.019
        • Finn A.P.
        • Thomas A.S.
        • Stinnett S.S.
        • Keenan R.T.
        • Grewal D.S.
        • Jaffe G.J.
        The role of cystoid macular edema as a marker in the progression of non-paraneoplastic autoimmune retinopathy.
        Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2018; 256: 1867-1873https://doi.org/10.1007/s00417-018-4084-8
        • Grewal D.S.
        • Jaffe G.J.
        • Keenan R.T.
        SARILUMAB FOR RECALCITRANT CYSTOID MACULAR EDEMA IN NON-PARANEOPLASTIC AUTOIMMUNE RETINOPATHY.
        Retin Cases Brief Rep. 2019; (Published online April 8)https://doi.org/10.1097/ICB.0000000000000872
        • Finn A.P.
        • Keenan R.T.
        • Jaffe G.J.
        RECONSTITUTION OF THE ELLIPSOID ZONE WITH TOCILIZUMAB IN AUTOIMMUNE RETINOPATHY.
        Retin Cases Brief Rep. 2020; 14: 297-300https://doi.org/10.1097/ICB.0000000000000766